PMID: 9558127Apr 29, 1998Paper

Population pharmacokinetics of vancomycin in Japanese adult patients

Therapeutic Drug Monitoring
M YasuharaR Hori

Abstract

Population pharmacokinetic parameters of vancomycin (VCM) in Japanese adult patients infected with methicillin-resistant Staphylococcus aureus (MRSA) were estimated using 1253 items of serum concentration data from 190 patients obtained in routine drug monitoring. The two-compartment linear model was adopted, and VCM clearance (CL) was correlated with the creatinine clearance (CLcr), which was observed or estimated by the Cockcroft-Gault equation. The population pharmacokinetic analysis program NONMEM with first-order conditional estimation method was used. The results showed VCM clearance to be linearly correlated with CLcr (CL [ml/min] = 0.797 x CLcr) when the estimated CLcr was <85 ml/min, but no linear relationship at higher than this level because of the lack of accuracy in the CLcr estimates. The interindividual variability of CL was 38.5%; K12 and K21 were 0.525 hr(-1) and 0.213 hr(-1), respectively. The distribution volume at steady state (V[SS]) was 60.71, with no significant dependence on the actual body weight. The interindividual variability of Vss was 25.4%. The calculated half-life (t1/2,beta) in a typical patient with CLcr of 85 ml/minute was 12.8 hours. Residual variability was 23.7%. These results were compared...Continue Reading

References

Oct 1, 1979·Annals of Internal Medicine·P Newfield, M F Roizen
Apr 1, 1976·Journal of Pharmacokinetics and Biopharmaceutics·R J Sawchuk, D E Zaske
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Dec 1, 1991·Clinical Pharmacology and Therapeutics·W L MaciasS K Scarim
Jun 1, 1991·Clinical Pharmacokinetics·R D PrykaS M Erdman
Jan 1, 1990·Therapeutic Drug Monitoring·C C TanE J Lee
Apr 1, 1990·The Journal of Antimicrobial Chemotherapy·M J RybakP H Chandrasekar
Jan 1, 1989·Therapeutic Drug Monitoring·R D PrykaJ C Rotschafer
Jan 1, 1988·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D L Brown, L S Mauro
May 1, 1988·Clinical Pharmacology and Therapeutics·T A GolperW M Bennett
Jun 1, 1988·Antimicrobial Agents and Chemotherapy·K A RodvoldL J Riff
Jul 1, 1986·Clinical Pharmacokinetics·G R MatzkeD R Guay
Aug 1, 1987·The American Journal of the Medical Sciences·M UaamnuichaiD C Brater
Nov 1, 1985·Pharmacotherapy·K D Lake, C D Peterson
Mar 1, 1981·Annals of Internal Medicine·R C MoelleringD J Greenblatt
Dec 1, 1984·The Journal of Antimicrobial Chemotherapy·R C Moellering
Dec 1, 1984·Clinical Pharmacology and Therapeutics·N R CutlerM Power
Apr 1, 1984·Antimicrobial Agents and Chemotherapy·G R MatzkeW F Keane
Apr 1, 1983·Antimicrobial Agents and Chemotherapy·N BrownG P Bodey
Sep 1, 1982·Annals of Internal Medicine·T C SorrellR Munro
Oct 1, 1981·Annals of Internal Medicine·P G Traber, D P Levine
Nov 1, 1981·Journal of Pharmacobio-dynamics·K YamaokaT Uno
Apr 1, 1995·Clinical Pharmacokinetics·W G LeaderM Castiglia
Oct 1, 1994·Therapeutic Drug Monitoring·M P DucharmeD J Edwards
Feb 1, 1994·Therapeutic Drug Monitoring·K A RodvoldK Vance-Bryan
Mar 1, 1993·Antimicrobial Agents and Chemotherapy·K Vance-BryanJ C Rotschafer
Feb 1, 1995·Journal of Pharmacokinetics and Biopharmaceutics·D K YuS J Weir
Apr 15, 1996·Annals of Internal Medicine·R HatalaD J Cook

❮ Previous
Next ❯

Citations

Jul 14, 2012·European Journal of Clinical Pharmacology·Yuko ShimamotoKatsuya Komori
Jan 12, 2008·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J ZhangJ Wu
Aug 17, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N ShimeN Fujita
Aug 5, 2000·International Journal of Antimicrobial Agents·D XuanC H Nightingale
Mar 21, 2009·The Journal of Antimicrobial Chemotherapy·A H ThomsonA M Lovering
May 2, 2012·TheScientificWorldJournal·Tunggul Adi PurwonugrohoPakwan Bunuparadah
Oct 27, 2006·Antimicrobial Agents and Chemotherapy·Yusuke TanigawaraKihachiro Shimizu
Nov 26, 2009·Antimicrobial Agents and Chemotherapy·Akihiro TanakaHiroaki Araki
Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Dolores Santos BuelgaMaría José García
Aug 29, 2001·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·M TanakaS Hirono
Oct 2, 2008·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Yuki IzuwaToshiaki Sendo
Jul 3, 2009·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Shinya SuzukiHitoshi Sato
Jan 5, 2010·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Shinichi SadohKazuhiro Tsukamoto
Jan 5, 2012·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Naoki KurodaToshiaki Sendo
Dec 14, 2011·Clinical Pharmacokinetics·Amélie MarsotNicolas Simon
May 10, 2012·Journal of Pharmaceutical Sciences·Takehito YamamotoHiroshi Suzuki
Dec 24, 2013·International Journal of Antimicrobial Agents·Tat-Ming NgVincent H Tam
Aug 27, 2005·British Journal of Clinical Pharmacology·Hussain Mulla, Suneel Pooboni
Sep 9, 2006·Journal of Clinical Pharmacy and Therapeutics·P Llopis-Salvia, N V Jiménez-Torres
Jul 27, 2010·British Journal of Clinical Pharmacology·Natalia RevillaMaría Del Mar Fernández de Gatta
Sep 1, 2005·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Makiko YoshidaKenji Matsuyama
May 16, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuaki MatsumotoToshimi Kimura
Nov 12, 2014·Clinical Pharmacokinetics·Danny TsaiJason A Roberts
Apr 25, 2018·Antimicrobial Agents and Chemotherapy·Saeed A AlqahtaniTurki B Albacker
Sep 5, 2017·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Shungo ImaiKen Iseki
Mar 11, 2015·Antimicrobial Agents and Chemotherapy·Anaïs GlatardSylvain Goutelle
May 18, 2016·Antimicrobial Agents and Chemotherapy·Laurent BourguignonSylvain Goutelle
Sep 20, 2019·Biological & Pharmaceutical Bulletin·Tomohiro IzumisawaNoriko Takahashi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.